Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

9.550 +0.330 (+3.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,089,341
Open 9.220
Bid (Size) 9.460 (1)
Ask (Size) 9.650 (12)
Prev. Close 9.220
Today's Range 9.200 - 9.610
52wk Range 2.410 - 12.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
From MindMed
Via Business Wire

Performance

YTD
+163.81%
+163.81%
1 Month
-12.30%
-12.30%
3 Month
+136.97%
+136.97%
6 Month
+238.65%
+238.65%
1 Year
+181.71%
+181.71%

More News

Read More
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
From MindMed
Via Business Wire
The Top 3 Small-Cap Stocks to Buy in April 2024
Via InvestorPlace
MindMed to Present at Upcoming May Medical Conferences
From MindMed
Via Business Wire
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
Via The Motley Fool
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Via Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Via Talk Markets
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
MindMed to Present at Upcoming April Medical Conferences
From Mind Medicine
Via Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
From MindMed
Via Business Wire
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
Via Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
The Next Great Biotech Boom Has Arrived
Via FinancialNewsMedia
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Via Benzinga
Exposures Product Safety
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
Via Talk Markets
Exposures Product Safety
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.